Centessa IPO Presentation Deck

ROADSHOW MATERIALS IS STRICTLY PROHIBITED IP ADDRESS. 51.89.224.65 Our Pipeline: Today's Focus PALLADIO BIOSCIENCIS ROADSHOW MATApcintexCTLY IP ADDRESS 51.89224.05 ZFactor OOO MORPHOGEN-IX PROGRAM Lixivaptan (Phase 3) SerpinPC (Phase 2) PROHIBITED MOA MGX292 (Lead Op/IND-Enabling) ROADSHOW MATE DEEP EXPERTISE Vasopressin V2 Receptor Antagonist PRINTING, COPYING, AND DISTR ZF874 (Phase 1) DDRESS: 51.80.224.65 MAIL [email protected] ZF887 (Lead Op/IND-enabling) Activated Protein C Inhibitor A1AT Folding Corrector BMP9 Engineered Variant Dr. Lorenzo Pellegrini Potentially more tolerable in autosomal Singly focused on lixivaptan 51. dominant polycystic kidney disease (ADPKD) EMAIL usen@ms with a differentiated profile from tolvaptan for past 6 years Dr. Trevor Baglin Lifelong hemophilia expert Dr. Jim Huntington 30 years studying the structure of Serpins PRINTING, COPY and A1AT KEY ATTRIBUTES CONF Potentially more tolerable rebalancing therapeutic that keeps clotting homeostasis intact and could be a one size fits all approach in hemophilia Potentially superior A1AT folding corrector based on structural understanding of the Z- pocket crystal structure Dr. Nick Morrell PRINTING, COPT Potentially disease modifying medicine Lifelong expert in the targeting a central causal pathway of PAH genetics of pulmonary MAIL@ms with human genetics support arterial hypertension CENTESSA 10

View entire presentation